Transforming growth factor-alpha

Drug Profile

Transforming growth factor-alpha

Latest Information Update: 07 Oct 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Antiulcers; Antivirals; Growth factors; Transforming growth factors
  • Mechanism of Action Transforming growth factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Oct 2002 Discontinued - Preclinical for Cancer in Italy (unspecified route)
  • 30 Jul 1998 No-Development-Reported for Cancer in Italy (Unknown route)
  • 12 Apr 1995 A study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top